Home » Biotechnology » India Stem Cell Contract Manufacturing Market

India Stem Cell Contract Manufacturing Market

India Stem Cell Contract Manufacturing Market By Scale of Operation (Commercial, Clinical, Preclinical); By Size of Contract Manufacturer (Large/Very Large, Mid-sized, Small-sized); By Source of Stem Cells (Allogenic, Autologous); By Type of Stem Cells (Adult Stem Cells (ASCs), Human Embryonic Stem Cells (HESCs), Induced Pluripotent Stem Cells (iPSCs)); By End-user (Biopharmaceutical Companies, Research Institutes, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
India Stem Cell Contract Manufacturing Market Size 2024	USD 54.44 million
India Stem Cell Contract Manufacturing Market, CAGR	14.98%
India Stem Cell Contract Manufacturing Market Size 2032	USD 166.35 million

Market Overview:

The India Stem Cell Contract Manufacturing Market is projected to grow from USD 54.44 million in 2024 to an estimated USD 166.35 million by 2032, with a compound annual growth rate (CAGR) of 14.98% from 2024 to 2032.

Several factors are driving the growth of the Indian stem cell contract manufacturing market. The increasing prevalence of chronic and degenerative diseases, such as diabetes, cardiovascular disorders, and neurodegenerative conditions, has amplified the need for innovative stem cell therapies. Furthermore, supportive government policies and initiatives, such as the National Guidelines for Stem Cell Research, have streamlined regulatory pathways and encouraged investment in the sector. The rising demand for cost-effective and scalable manufacturing solutions has also spurred the growth of CMOs, providing a vital infrastructure for clinical and commercial-scale production. In addition, technological advancements, including 3D bioprinting and automated manufacturing processes, have enhanced the efficiency and quality of stem cell production, further fueling market growth.

Regionally, metropolitan cities such as Mumbai, Bengaluru, Hyderabad, and Pune dominate the Indian stem cell contract manufacturing landscape due to their well-established biotech clusters, skilled workforce, and robust research ecosystems. Maharashtra leads the market, driven by substantial investments in biotech infrastructure and the presence of prominent players in the stem cell domain. Karnataka, particularly Bengaluru, is emerging as a hub for innovation, supported by numerous start-ups, research institutions, and favorable government policies. Other regions, including Tamil Nadu and Delhi-NCR, are also gaining traction owing to increasing collaborations between research centers and industry stakeholders. The competitive landscape is marked by domestic CMOs as well as collaborations with international firms aiming to leverage India’s cost advantages and scientific expertise.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights:

The India Stem Cell Contract Manufacturing Market is projected to grow significantly, reaching USD 166.35 million by 2032, with a robust CAGR of 14.98% from 2024 to 2032.
The increasing prevalence of chronic and degenerative diseases, such as diabetes and neurodegenerative conditions, continues to drive the demand for innovative stem cell therapies and manufacturing solutions.
Technological advancements, including 3D bioprinting, automated bioreactor systems, and AI-driven quality control, are enhancing the efficiency and scalability of stem cell manufacturing.
Supportive regulatory frameworks, such as the National Guidelines for Stem Cell Research, streamline approval processes and attract investment, fostering the market’s growth.
Cities like Mumbai, Bengaluru, Hyderabad, and Pune dominate the market due to their established biotech clusters and skilled workforce, with Maharashtra holding the largest market share.
Collaborations between domestic CMOs and international firms are driving innovation, enabling India to leverage its cost-effective manufacturing infrastructure and cater to global demand.
Challenges such as high development costs, regulatory complexities, and limited awareness of stem cell therapies need to be addressed to unlock the market’s full potential.

Market Drivers:

Rising Prevalence of Chronic and Degenerative Diseases

The growing burden of chronic and degenerative diseases, including diabetes, cardiovascular disorders, neurodegenerative conditions, and autoimmune diseases, is a major driver of the India stem cell contract manufacturing market. These conditions necessitate innovative treatment options, and stem cell therapies have emerged as a promising solution. The increasing demand for regenerative therapies has spurred clinical research and the commercialization of stem cell-based products, thereby driving the need for scalable and efficient manufacturing services. For instance, Stempeutics Research has developed Stempeucel, an allogeneic stem cell therapy for critical limb ischemia, which has shown promising results in clinical trials.

Supportive Regulatory Environment and Government Initiatives

India’s regulatory framework has been instrumental in fostering the growth of the stem cell market. Policies such as the National Guidelines for Stem Cell Research provide clarity and streamline approval processes for clinical trials and commercialization. These measures, along with funding support for biotechnology start-ups and research institutions, have encouraged investment in stem cell research and manufacturing. The Indian government’s focus on advancing the biotechnology sector aligns with the global trends in regenerative medicine, further boosting the market’s growth prospects. For example, the Department of Biotechnology (DBT) has allocated significant funds to support stem cell research projects

Technological Advancements in Stem Cell Manufacturing

The adoption of advanced technologies in stem cell manufacturing has significantly enhanced the efficiency and scalability of production processes. Innovations such as 3D bioprinting, automated bioreactor systems, and closed-system manufacturing platforms have improved yield and reduced contamination risks. These advancements are particularly valuable in addressing the complexities of large-scale production required for commercial applications. Additionally, the integration of artificial intelligence and machine learning in quality control and process optimization ensures high precision and consistency in stem cell production. For instance, US-based StemCures has invested $54 million to establish India’s largest stem cell manufacturing laboratory in Hyderabad, incorporating state-of-the-art technologies.

Growing Collaborations and Outsourcing Opportunities

Collaborative efforts between domestic and international players are a key driver of market growth. Indian contract manufacturing organizations (CMOs) are increasingly forming partnerships with global biopharmaceutical companies to leverage India’s cost-effective infrastructure and skilled workforce. These collaborations provide access to advanced technologies and global expertise, enabling Indian CMOs to expand their service portfolios and cater to international demand. The trend of outsourcing manufacturing to India is further fueled by the rising costs of stem cell production in developed markets, positioning the country as a strategic hub for stem cell contract manufacturing. For example, Stempeutics Research has partnered with Cipla to commercialize Stempeucel, enhancing its reach and impac

Market Trends:

Increasing Demand for Scalable Manufacturing Solutions

The India stem cell contract manufacturing market is witnessing a surge in demand for scalable manufacturing solutions to cater to the growing need for clinical and commercial-scale production. With the rise in clinical trials and commercialization of stem cell therapies, CMOs are increasingly adopting advanced bioprocessing technologies to meet industry demands. Automation and digitization in manufacturing processes, including real-time monitoring systems and data-driven optimization, are becoming standard practices, enabling high-quality and cost-efficient production. For instance, Stempeutics Research has implemented automated bioreactor systems to enhance the scalability and efficiency of their stem cell production

Advancements in Allogenic Stem Cell Applications

While autologous therapies have been dominant, there is a growing shift toward allogenic stem cell applications due to their potential for broader usage and lower production costs. Allogenic therapies, derived from donor cells, offer scalability and convenience in large-scale production, making them attractive for CMOs and biopharmaceutical companies. This trend is further supported by advancements in cryopreservation techniques, which ensure the viability and efficacy of stem cells during storage and transportation. For example, Stempeutics Research’s Stempeucel, an allogeneic stem cell therapy, has shown promising results in treating critical limb ischemia

Emergence of Innovative Research Partnerships

Collaborations between academic institutions, start-ups, and established pharmaceutical companies are on the rise, driving innovation in the market. Research partnerships focus on exploring new therapeutic areas, such as immunotherapy and neurodegenerative disease treatment. Additionally, international firms are increasingly partnering with Indian CMOs to leverage the country’s cost-effective manufacturing infrastructure and scientific expertise, further enhancing the global competitiveness of India’s stem cell market. For instance, SKAN Research Trust has partnered with the University of Cambridge to advance stem cell research and develop new therapies for neurodegenerative diseases.

Focus on Personalized Medicine and Regenerative Therapies

The growing emphasis on personalized medicine and regenerative therapies is shaping the future of the market. Stem cell-based approaches tailored to individual patient needs are gaining momentum, creating opportunities for CMOs to provide customized manufacturing solutions. This trend aligns with the increasing adoption of induced pluripotent stem cells (iPSCs) for their versatility in generating patient-specific treatments. Moreover, the integration of artificial intelligence and machine learning in manufacturing processes is enabling precise quality control and process optimization, ensuring better patient outcomes and driving market growth. For instance, Thermo Fisher Scientific Inc. has invested heavily in R&D to advance cell therapy solutions, leveraging iPSCs to develop treatments that are more effective for individual patients

Market Challenges Analysis:

High Costs of Development and Manufacturing

Despite India’s cost advantages, the development and manufacturing of stem cell therapies remain expensive due to the need for specialized facilities, skilled personnel, and advanced technologies. The costs associated with ensuring compliance with stringent quality standards and regulatory requirements further add to the financial burden for contract manufacturing organizations (CMOs).

Regulatory Complexities

While supportive government initiatives exist, navigating the regulatory landscape can be challenging for CMOs. The evolving nature of stem cell regulations, coupled with varying international standards, creates uncertainties that can delay product approvals and hinder market growth. Ensuring compliance with global quality benchmarks while adhering to local guidelines remains a critical challenge.

Limited Awareness and Adoption

The adoption of stem cell-based therapies is still limited in India due to a lack of widespread awareness among healthcare providers and patients. Concerns regarding the efficacy and safety of stem cell treatments further hinder their acceptance. Overcoming these barriers requires robust education and marketing efforts, which can be resource-intensive for market players.

Infrastructure and Skilled Workforce Gaps

While metropolitan regions like Bengaluru and Pune boast advanced biotechnology infrastructure, other regions lag in terms of facilities and technical expertise. A shortage of trained professionals in areas such as bioprocessing and quality control presents a significant restraint. Addressing these gaps is essential for the market to achieve its full potential.

Ethical Concerns and Public Perception

Ethical debates surrounding the use of human embryonic stem cells (HESCs) remain a challenge, affecting public perception and policy decisions. This issue requires careful handling to balance scientific progress with ethical considerations, ensuring public trust in the industry.

Market Opportunities:

The India Stem Cell Contract Manufacturing Market offers significant growth opportunities driven by the rising global demand for stem cell-based therapies and advancements in biotechnology. India’s cost-efficient manufacturing capabilities, coupled with a skilled workforce and advanced infrastructure, position the country as an attractive hub for contract manufacturing organizations (CMOs). The increasing prevalence of chronic and degenerative diseases, such as diabetes, cardiovascular disorders, and neurodegenerative conditions, further bolsters the demand for innovative stem cell therapies. With supportive government initiatives, such as the National Guidelines for Stem Cell Research, regulatory pathways are streamlined, enabling faster approvals and fostering investment in the sector.

Expanding collaborations between domestic CMOs and international pharmaceutical companies represent another key market opportunity. These partnerships leverage India’s cost advantages and technological expertise to cater to global demand. Technological innovations, including 3D bioprinting, scalable bioreactor systems, and automation, enable efficient production, enhancing the market’s potential for growth. The increasing focus on personalized medicine and regenerative therapies offers CMOs a chance to develop tailored solutions for diverse therapeutic needs. Additionally, the growth of clinical trials and a rising number of biopharmaceutical start-ups in metropolitan regions such as Bengaluru, Pune, and Hyderabad provide ample opportunities to cater to preclinical and clinical-scale production. The confluence of these factors ensures a robust future for the India stem cell contract manufacturing market, making it a pivotal player in the global stem cell industry.

Market Segmentation Analysis:

The India Stem Cell Contract Manufacturing Market is segmented based on scale of operation, size of contract manufacturer, source and type of stem cells, and end-users. These segments collectively shape the market dynamics, catering to diverse requirements across research and commercial applications.

By Scale of Operation, the market is divided into commercial, clinical, and preclinical segments. The clinical segment dominates due to the rising number of stem cell therapy trials, while the commercial segment is growing steadily with increasing approvals for stem cell-based therapies.

By Size of Contract Manufacturer, the market includes large/very large, mid-sized, and small-sized CMOs. Large CMOs lead the segment, offering advanced capabilities and scalability, whereas small and mid-sized CMOs focus on niche services and cost-efficiency.

By Source of Stem Cells, the market is categorized into allogenic and autologous sources. Allogenic stem cells hold a larger share due to their broader applications, but autologous stem cells are gaining traction in personalized medicine.

By Type of Stem Cells, the market is segmented into adult stem cells (ASCs), human embryonic stem cells (HESCs), and induced pluripotent stem cells (iPSCs). ASCs dominate due to their established use in regenerative therapies, while iPSCs are rapidly emerging due to their versatility and potential for innovation.

By End-user, the market is segmented into biopharmaceutical companies, research institutes, and others. Biopharmaceutical companies are the primary contributors, leveraging contract manufacturing for scalable production, while research institutes drive demand through clinical and preclinical activities.

Segmentation:

By Scale of Operation

Commercial
Clinical
Preclinical

By Size of Contract Manufacturer

Large/Very Large
Mid-sized
Small-sized

By Source of Stem Cells

Allogenic
Autologous

By Type of Stem Cells

Adult Stem Cells (ASCs)
Human Embryonic Stem Cells (HESCs)
Induced Pluripotent Stem Cells (iPSCs)

By End-user

Biopharmaceutical companies
Research Institutes
Others

Regional Analysis:

The India Stem Cell Contract Manufacturing Market is dominated by key metropolitan regions, each contributing significantly to the industry’s growth due to their established biotechnology infrastructure, skilled workforce, and supportive policies. The regional landscape is shaped by the presence of biotech clusters and research centers that drive innovation and attract investments.

Maharashtra holds the largest market share, accounting for approximately 35% of the overall revenue. The state benefits from its well-developed biotechnology ecosystem, with Mumbai and Pune serving as key hubs for stem cell research and manufacturing. Prominent CMOs and pharmaceutical companies based in these cities contribute to Maharashtra’s leadership in the sector.

Karnataka, particularly Bengaluru, represents around 25% of the market share. Known as the “Silicon Valley of India,” Bengaluru has emerged as a biotechnology hub with numerous start-ups, research institutions, and government-backed initiatives. The city’s focus on innovation and collaboration has positioned Karnataka as a major player in stem cell manufacturing.

Telangana accounts for approximately 20% of the market, with Hyderabad serving as the epicenter of its biotech activities. The city is home to several prominent life sciences parks, research centers, and contract manufacturing organizations. Its strategic location and robust infrastructure make it a preferred destination for both domestic and international collaborations.

Tamil Nadu holds about 10% of the market share, driven by Chennai’s growing prominence in biotechnology and healthcare. The region benefits from a strong academic network and increasing investments in research and development.

Delhi-NCR contributes nearly 8% to the market, leveraging its proximity to policy-making bodies, premier research institutions, and an expanding healthcare infrastructure. The region is gaining traction as a key player in the sector.

Other regions, collectively accounting for the remaining 2%, are gradually establishing their presence through state-backed initiatives and private investments in biotechnology. These regions include Gujarat, Andhra Pradesh, and Kerala, which are focusing on enhancing their biotech capabilities.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

WuXi AppTec
Boehringer Ingelheim
Catalent Inc.
Cytiva
AbbVie Inc.
AGC Biologics
FUJIFILM Diosynth Biotechnologies
Samsung Biologics
Thermo Fisher Scientific Inc.
Cytovance Biologics

Competitive Analysis:

The India Stem Cell Contract Manufacturing Market is characterized by increasing competition among domestic and international players striving to capture a growing demand for stem cell-based therapies. Domestic contract manufacturing organizations (CMOs) leverage India’s cost advantages, skilled workforce, and supportive regulatory environment to offer scalable and efficient solutions. For instance, Stempeutics Research has commercialized India’s first allogeneic stem cell therapy, Stempeucel, which is designed to rejuvenate blood flow in ischemic tissues. Key players focus on strategic partnerships, research collaborations, and technology integration to enhance their production capabilities and service portfolios. International firms are entering the market through joint ventures and alliances to tap into India’s emerging biotech ecosystem and cost-efficient manufacturing infrastructure. The market also sees competition driven by advancements in 3D bioprinting, automated bioreactors, and other cutting-edge technologies. Companies investing in quality standards, regulatory compliance, and intellectual property protection gain a competitive edge. The growing emphasis on innovation and collaboration ensures a dynamic and rapidly evolving competitive landscape.

Recent Developments:

In November 2024, FUJIFILM Diosynth Biotechnologies launched the first phase of its global CDMO ecosystem expansion at its Hillerød site in Denmark. This phase added six mammalian cell bioreactors, increasing the site’s capacity to 12 x 20,000 L bioreactors, with plans for further expansion by mid-2025.
In January 2024, AbbVie and Umoja Biopharma announced a strategic collaboration to develop in-situ generated CAR-T cell therapy candidates for oncology. This partnership leverages Umoja’s VivoVec™ gene delivery platform and AbbVie’s oncology expertise to potentially expand the patient populations benefiting from CAR-T therapies.
In December 2024, Lonza announced the expansion of its capsule manufacturing capacity in India and China. New capsule manufacturing lines were added at facilities in Rewari, India, and Suzhou, China, to support the production of high-quality hard gelatin capsules for the pharmaceutical and nutraceutical industries. This move is part of Lonza’s strategy to enhance its competitiveness and meet the growing demand for capsules in the APAC region.

Market Concentration & Characteristics:

The India Stem Cell Contract Manufacturing Market exhibits a moderately concentrated landscape, characterized by the presence of established domestic players and collaborations with global firms. Key players leverage advanced technologies and cost-efficient production processes, making India an attractive destination for outsourcing. The market is marked by the growing number of contract manufacturing organizations (CMOs) that provide scalable and flexible solutions to cater to the diverse needs of pharmaceutical and biotechnology companies. High demand for stem cell-based therapies in regenerative medicine, drug development, and personalized treatments drives market activities. The industry’s reliance on stringent quality standards and regulatory compliance underscores the importance of technical expertise and infrastructure. Emerging biotech clusters in cities like Bengaluru and Pune highlight the regional competitiveness, fostering innovation and investment. The market’s evolution is shaped by a blend of cost advantages, skilled professionals, and technological advancements, ensuring robust growth potential.

Report Coverage:

The research report offers an in-depth analysis based on By Scale of Operation, By Size of Contract Manufacturer, By Source of Stem Cells, By Type of Stem Cells and By End-user.It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

The India stem cell contract manufacturing market is poised for robust expansion, driven by a growing demand for innovative therapeutic solutions.
Increasing prevalence of chronic and degenerative diseases will continue to fuel the adoption of stem cell therapies.
Government support through streamlined regulations and funding initiatives is expected to strengthen the market ecosystem.
Advancements in technologies like 3D bioprinting and automated bioreactor systems will enhance production efficiency and scalability.
Collaboration between domestic and international players will boost expertise sharing and technological integration.
Cost advantages and India’s skilled workforce will make the country an attractive hub for global stem cell manufacturing outsourcing.
Expanding clinical trials for stem cell-based treatments will create new opportunities for contract manufacturers.
The emergence of new biotech clusters in metropolitan cities will provide additional infrastructure and innovation.
Increasing public and private investments in biotechnology and healthcare will further accelerate market growth.
Enhanced focus on personalized medicine and regenerative therapies will drive sustained demand in the long term.

CHAPTER NO. 1 : INTRODUCTION 19

1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.2. Key Benefits for Stakeholders 19

1.3. Target Audience 20

1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. India Stem Cell Contract Manufacturing Market Snapshot 21

2.2. India Stem Cell Contract Manufacturing Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : INDIA STEM CELL CONTRACT MANUFACTURING MARKET – INDUSTRY ANALYSIS 23

3.1. Introduction 23

3.2. Market Drivers 24

3.3. Supportive Regulatory Framework 24

3.4. Demand for Specialized Manufacturing Expertise 25

3.5. Market Restraints 26

3.6. Regulatory Complexity 26

3.7. Market Opportunities 27

3.8. Market Opportunity Analysis 27

3.9. Porter’s Five Forces Analysis 28

CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE 29

4.1. Company Market Share Analysis – 2023 29

4.1.1. India Stem Cell Contract Manufacturing Market: Company Market Share, by Volume, 2023 29

4.1.2. India Stem Cell Contract Manufacturing Market: Company Market Share, by Revenue, 2023 30

4.1.3. India Stem Cell Contract Manufacturing Market: Top 6 Company Market Share, by Revenue, 2023 30

4.1.4. India Stem Cell Contract Manufacturing Market: Top 3 Company Market Share, by Revenue, 2023 31

4.2. India Stem Cell Contract Manufacturing Market Company Revenue Market Share, 2023 32

4.3. Company Assessment Metrics, 2023 33

4.3.1. Stars 33

4.3.2. Emerging Leaders 33

4.3.3. Pervasive Players 33

4.3.4. Participants 33

4.4. Start-ups /SMEs Assessment Metrics, 2023 33

4.4.1. Progressive Companies 33

4.4.2. Responsive Companies 33

4.4.3. Dynamic Companies 33

4.4.4. Starting Blocks 33

4.5. Strategic Developments 34

4.5.1. Acquisitions & Mergers 34

New Product Launch 34

Regional Expansion 34

4.6. Key Players Product Matrix 35

CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS 36

5.1. PESTEL 36

5.1.1. Political Factors 36

5.1.2. Economic Factors 36

5.1.3. Social Factors 36

5.1.4. Technological Factors 36

5.1.5. Environmental Factors 36

5.1.6. Legal Factors 36

5.2. Adjacent Market Analysis 36

CHAPTER NO. 6 : INDIA STEM CELL CONTRACT MANUFACTURING MARKET – BY SCALE OF OPERATION SEGMENT ANALYSIS 37

6.1. India Stem Cell Contract Manufacturing Market Overview, by Scale of Operation Segment 37

6.1.1. India Stem Cell Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 38

6.1.2. India Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Scale of Operation 39

6.1.3. Incremental Revenue Growth Opportunity, by Scale of Operation, 2024 – 2032 39

6.1.4. India Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 40

6.2. Commercial 41

6.3. Clinical 42

6.4. Preclinical 43

CHAPTER NO. 7 : INDIA STEM CELL CONTRACT MANUFACTURING MARKET – BY SIZE OF CONTRACT MANUFACTURER SEGMENT ANALYSIS 44

7.1. India Stem Cell Contract Manufacturing Market Overview, by Size of Contract Manufacturer Segment 44

7.1.1. India Stem Cell Contract Manufacturing Market Revenue Share, By Size of Contract Manufacturer, 2023 & 2032 45

7.1.2. India Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Size of Contract Manufacturer 46

7.1.3. Incremental Revenue Growth Opportunity, by Size of Contract Manufacturer, 2024 – 2032 46

7.1.4. India Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018, 2023, 2027 & 2032 47

7.2. Large/Very Large 48

7.3. Mid-sized 49

7.4. Small-sized 50

CHAPTER NO. 8 : INDIA STEM CELL CONTRACT MANUFACTURING MARKET – BY END-USER SEGMENT ANALYSIS 51

8.1. India Stem Cell Contract Manufacturing Market Overview, by End-user Segment 51

8.1.1. India Stem Cell Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 52

8.1.2. India Stem Cell Contract Manufacturing Market Attractiveness Analysis, By End-user 53

8.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 53

8.1.4. India Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 54

8.2. Biopharmaceutical companies 55

8.3. Research Institutes 56

8.4. Others 57

CHAPTER NO. 9 : INDIA STEM CELL CONTRACT MANUFACTURING MARKET – BY SOURCE OF STEM CELLS SEGMENT ANALYSIS 58

9.1. India Stem Cell Contract Manufacturing Market Overview, by Source of Stem Cells Segment 58

9.1.1. India Stem Cell Contract Manufacturing Market Revenue Share, By Source of Stem Cells, 2023 & 2032 59

9.1.2. India Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Source of Stem Cells 60

9.1.3. Incremental Revenue Growth Opportunity, by Source of Stem Cells, 2024 – 2032 60

9.1.4. India Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018, 2023, 2027 & 2032 61

9.2. Allogenic 62

9.3. Autologous 63

CHAPTER NO. 10 : INDIA STEM CELL CONTRACT MANUFACTURING MARKET – BY TYPE OF STEM CELLS SEGMENT ANALYSIS 64

10.1. India Stem Cell Contract Manufacturing Market Overview, by Type of Stem Cells Segment 64

10.1.1. India Stem Cell Contract Manufacturing Market Revenue Share, By Type of Stem Cells, 2023 & 2032 65

10.1.2. India Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Type of Stem Cells 66

10.1.3. Incremental Revenue Growth Opportunity, by Type of Stem Cells, 2024 – 2032 66

10.1.4. India Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018, 2023, 2027 & 2032 67

10.2. Adult Stem Cells (ASCs) 68

10.3. Human Embryonic Stem Cells (HESCs) 69

10.4. Induced Pluripotent Stem Cells (iPSCs) 70

CHAPTER NO. 11 : STEM CELL CONTRACT MANUFACTURING MARKET – ANALYSIS 71

11.1.1. India Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 71

11.1.2. India Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018 – 2023 (USD Million) 72

11.1.3. India Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 73

11.1.4. India Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018 – 2023 (USD Million) 74

11.1.5. India Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018 – 2023 (USD Million) 75

CHAPTER NO. 12 : COMPANY PROFILES 76

12.1. Lonza Group 76

12.1.1. Company Overview 76

12.1.2. Product Portfolio 76

12.1.3. Swot Analysis 76

12.1.4. Business Strategy 77

12.1.5. Financial Overview 77

12.2. WuXi AppTec 78

12.3. Boehringer Ingelheim 78

12.4. Catalent Inc. 78

12.5. Cytiva 78

12.6. AbbVie Inc. 78

12.7. AGC Biologics 78

12.8. FUJIFILM Diosynth Biotechnologies 78

12.9. Samsung Biologics 78

12.10. Thermo Fisher Scientific Inc. 78

12.11. Cytovance Biologics 78

List of Figures

FIG NO. 1. India Stem Cell Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for India Stem Cell Contract Manufacturing Market 28

FIG NO. 3. Company Share Analysis, 2023 29

FIG NO. 4. Company Share Analysis, 2023 30

FIG NO. 5. Company Share Analysis, 2023 30

FIG NO. 6. Company Share Analysis, 2023 31

FIG NO. 7. India Stem Cell Contract Manufacturing Market – Company Revenue Market Share, 2023 32

FIG NO. 8. India Stem Cell Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 38

FIG NO. 9. Market Attractiveness Analysis, By Scale of Operation 39

FIG NO. 10. Incremental Revenue Growth Opportunity by Scale of Operation, 2024 – 2032 39

FIG NO. 11. India Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 40

FIG NO. 12. India Stem Cell Contract Manufacturing Market for Commercial, Revenue (USD Million) 2018 – 2032 41

FIG NO. 13. India Stem Cell Contract Manufacturing Market for Clinical, Revenue (USD Million) 2018 – 2032 42

FIG NO. 14. India Stem Cell Contract Manufacturing Market for Preclinical, Revenue (USD Million) 2018 – 2032 43

FIG NO. 15. India Stem Cell Contract Manufacturing Market Revenue Share, By Size of Contract Manufacturer, 2023 & 2032 45

FIG NO. 16. Market Attractiveness Analysis, By Size of Contract Manufacturer 46

FIG NO. 17. Incremental Revenue Growth Opportunity by Size of Contract Manufacturer, 2024 – 2032 46

FIG NO. 18. India Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018, 2023, 2027 & 2032 47

FIG NO. 19. India Stem Cell Contract Manufacturing Market for Large/Very Large, Revenue (USD Million) 2018 – 2032 48

FIG NO. 20. India Stem Cell Contract Manufacturing Market for Mid-sized, Revenue (USD Million) 2018 – 2032 49

FIG NO. 21. India Stem Cell Contract Manufacturing Market for Small-sized, Revenue (USD Million) 2018 – 2032 50

FIG NO. 22. India Stem Cell Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 52

FIG NO. 23. Market Attractiveness Analysis, By End-user 53

FIG NO. 24. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 53

FIG NO. 25. India Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 54

FIG NO. 26. India Stem Cell Contract Manufacturing Market for Biopharmaceutical companies, Revenue (USD Million) 2018 – 2032 55

FIG NO. 27. India Stem Cell Contract Manufacturing Market for Research Institutes, Revenue (USD Million) 2018 – 2032 56

FIG NO. 28. India Stem Cell Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 57

FIG NO. 29. India Stem Cell Contract Manufacturing Market Revenue Share, By Source of Stem Cells, 2023 & 2032 59

FIG NO. 30. Market Attractiveness Analysis, By Source of Stem Cells 60

FIG NO. 31. Incremental Revenue Growth Opportunity by Source of Stem Cells, 2024 – 2032 60

FIG NO. 32. India Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018, 2023, 2027 & 2032 61

FIG NO. 33. India Stem Cell Contract Manufacturing Market for Allogenic, Revenue (USD Million) 2018 – 2032 62

FIG NO. 34. India Stem Cell Contract Manufacturing Market for Autologous, Revenue (USD Million) 2018 – 2032 63

FIG NO. 35. India Stem Cell Contract Manufacturing Market Revenue Share, By Type of Stem Cells, 2023 & 2032 65

FIG NO. 36. Market Attractiveness Analysis, By Type of Stem Cells 66

FIG NO. 37. Incremental Revenue Growth Opportunity by Type of Stem Cells, 2024 – 2032 66

FIG NO. 38. India Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018, 2023, 2027 & 2032 67

FIG NO. 39. India Stem Cell Contract Manufacturing Market for Adult Stem Cells (ASCs), Revenue (USD Million) 2018 – 2032 68

FIG NO. 40. India Stem Cell Contract Manufacturing Market for Human Embryonic Stem Cells (HESCs), Revenue (USD Million) 2018 – 2032 69

FIG NO. 41. India Stem Cell Contract Manufacturing Market for Induced Pluripotent Stem Cells (iPSCs), Revenue (USD Million) 2018 – 2032 70

List of Tables

TABLE NO. 1. : India Stem Cell Contract Manufacturing Market: Snapshot 21

TABLE NO. 2. : Drivers for the India Stem Cell Contract Manufacturing Market: Impact Analysis 24

TABLE NO. 3. : Restraints for the India Stem Cell Contract Manufacturing Market: Impact Analysis 26

TABLE NO. 4. : India Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 71

TABLE NO. 5. : India Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 71

TABLE NO. 6. : India Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018 – 2023 (USD Million) 72

TABLE NO. 7. : India Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2024 – 2032 (USD Million) 72

TABLE NO. 8. : India Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 73

TABLE NO. 9. : India Stem Cell Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 73

TABLE NO. 10. : India Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018 – 2023 (USD Million) 74

TABLE NO. 11. : India Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2024 – 2032 (USD Million) 74

TABLE NO. 12. : India Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018 – 2023 (USD Million) 75

TABLE NO. 13. : India Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2024 – 2032 (USD Million) 75

Frequently Asked Questions

What is the projected growth of the India Stem Cell Contract Manufacturing Market?

The market is expected to grow from USD 54.44 million in 2024 to USD 166.35 million by 2032, with a CAGR of 14.98% during the forecast period.

What factors are driving the market growth?

Key drivers include the increasing prevalence of chronic and degenerative diseases, supportive government policies, demand for cost-effective manufacturing solutions, and advancements in technologies like 3D bioprinting and automated processes.

Which regions dominate the market in India?

Metropolitan cities like Mumbai, Bengaluru, Hyderabad, and Pune lead the market due to their biotech clusters, skilled workforce, and research infrastructure. Maharashtra and Karnataka are prominent regions for growth.

What challenges does the market face?

Challenges include high costs of stem cell therapy development, regulatory complexities, and the need for skilled personnel and advanced infrastructure to meet production demands.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$8699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –